Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome

Published:2018-04-16 Issue:13 Volume:124 Page:2758-2765
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Assi Rita¹^ORCID,Kantarjian Hagop M.¹^ORCID,Kadia Tapan M.¹^ORCID,Pemmaraju Naveen¹,Jabbour Elias¹^ORCID,Jain Nitin¹,Daver Naval¹^ORCID,Estrov Zeev¹,Uehara Taisuke²,Owa Takashi²,Cortes Jorge E.¹,Borthakur Gautam¹

Affiliation:

1. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Tsukuba Research Laboratories, Eisai Company, Ltd; Tsukuba Ibaraki Japan

Funder

Eisai Pharmaceuticals

University of Texas MD Anderson Cancer Center

University of Texas MD Anderson Cancer Center Leukemia Specialized Programs of Research Excellence

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.31398/fullpdf

Reference28 articles.

1. Emerging therapeutic drugs for AML;Stein;Blood,2016

2. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center;Walter;Leukemia,2015

3. Prognostic index for adult patients with acute myeloid leukemia in first relapse;Breems;J Clin Oncol,2005

4. Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience;Pemmaraju;Am J Hematol,2015

5. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle;Owa;J Med Chem,1999

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in anticancer mechanisms of molecular glue degraders: focus on RBM39-dgrading synthetic sulfonamide such as indisulam, E7820, tasisulam, and chloroquinoxaline sulfonamide;Genes & Genomics;2024-09-13

2. Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy;Critical Reviews in Oncology/Hematology;2024-09

3. Targeting RBM39 through indisulam induced mis-splicing of mRNA to exert anti-cancer effects in T-cell acute lymphoblastic leukemia;Journal of Experimental & Clinical Cancer Research;2024-07-24

4. Pre‐mRNA Splicing Modulation;Methods and Principles in Medicinal Chemistry;2024-07-05

5. DCAF15 control of cohesin dynamics sustains acute myeloid leukemia;Nature Communications;2024-07-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3